secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001104659-26-000066
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Outlook Therapeutics' ONS-5010 BLA for wet AMD
--------------------------------------------------------------------------------

- FDA CRL states additional mechanistic/natural history data does not alter prior conclusion; confirmatory efficacy evidence needed but not defined.
- Outlook Therapeutics disagrees with decision and is exploring all available U.S. approval pathways.
- ONS-5010 (LYTENAVA) already approved in EU and UK; commercially available in Germany and UK since June 2025.
- CEO Bob Jahr reaffirms commitment to bringing first FDA-approved on-label bevacizumab for wet AMD to U.S. patients.
- Company continues to expand European presence and seek commercial partners outside Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/0001104659-26-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer